PTC Therapeutics, Inc. EBIT Margin

EBIT Margin of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT Margin growth rates and interactive chart. Earnings before interest and taxes margin is an indicator of a company's profitability. Calculated as earnings before interest and taxes (EBIT) divided by revenue. It is useful for comparison of companies with different debt levels and tax rates. And EBIT margin gives a clear picture about the underlying profitability of a company's core operations. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes.


Highlights and Quick Summary

  • EBIT Margin for the quarter ending September 29, 2021 was -67.09% (a -20.53% decrease compared to previous quarter)
  • Year-over-year quarterly EBIT Margin decreased by -17.25%
  • Annual EBIT Margin for 2020 was -158.88% (a 26.49% increase from previous year)
  • Annual EBIT Margin for 2019 was -125.61% (a 43.72% increase from previous year)
  • Annual EBIT Margin for 2018 was -87.4% (a 32.12% increase from previous year)
  • Twelve month EBIT Margin ending September 29, 2021 was -78.44% (a 6.32% increase compared to previous quarter)
  • Twelve month trailing EBIT Margin decreased by -30.82% year-over-year
Trailing EBIT Margin for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-78.44% -73.78% -101.5% -113.39%
Visit stockrow.com/PTCT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT Margin of PTC Therapeutics, Inc.

Most recent EBIT Marginof PTCT including historical data for past 10 years.

Interactive Chart of EBIT Margin of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -67.09% -84.42% -83.22%
2020 -81.08% -46.56% -248.9% -136.23% -158.88%
2019 -75.46% -84.68% -45.32% -129.03% -125.61%
2018 -52.28% -90.0% -8.11% -29.87% -87.4%
2017 6.99% -73.81% -26.06% -99.28% -66.15%
2016 -99.21% -139.49% -233.86% -203.45% -313.3%
2015 -378.52% -432.0% -570.21% -508.83% -454.58%
2014 -254.65% -1629.34% -1512.76% -154.19% -393.79%
2013 -410.18% -26.25% -210.87% -120.08% -130.85%
2012 -90.83% -98.06% -98.85% -49.66% -78.97%
2011 29.01%

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.